Healthcare AI M&A: what is happening now?
In our healthcare AI market deck, you will find everything you need to understand the market
SUMMARY
Healthcare AI M&A: what is happening now? The answer is clear: healthcare AI M&A is accelerating, and the market is moving from isolated AI experiments into active platform consolidation.
We found 30 relevant healthcare AI M&A deals between 29 June 2024 and 29 June 2026, including 21 in the most recent 12 months. That is no longer a thin market where one or two transactions can distort the story.
The acceleration is the first thing to notice. Deal count moved from 9 in the earlier 12-month period to 21 in the latest one, meaning the recent period was roughly 2.3x more active.
The most important shift is not just volume. The market has expanded from obvious AI categories, like drug discovery and imaging, into the operating layer of healthcare: billing, claims, documentation, patient access, engagement, payment integrity and health-plan activation.
The biggest buyers are not simply buying models. They are buying workflow control, healthcare-specific data, distribution, customer trust and the ability to place AI inside processes where money or clinical work actually moves.
Administrative AI is one of the densest areas of activity. Revenue cycle management, payment integrity, actuarial intelligence, claims review and patient access keep appearing because buyers can connect those tools to faster cash collection, fewer denials and less operational waste.
Radiology and imaging remain the clearest clinical consolidation zone. RadNet / DeepHealth and GE HealthCare are not just buying image-reading features; they are building broader imaging platforms around workflow, cloud software, datasets and distribution.
Healthcare AI acquirers are now paying serious money, even if most values remain undisclosed. The disclosed and semi-disclosed value pool exceeds $17B, with several large transactions above $1B and a middle layer of $80M to $300M deals.
The market is global in technology supply but U.S.-anchored in monetization. European and U.K.-linked AI assets are being bought, but many of the strongest commercial use cases are tied to U.S. healthcare complexity, reimbursement, payer workflows and software budgets.
AI drug discovery is still alive, but it is more selective than the broader healthcare AI M&A market. Buyers want AI tied to pipelines, proprietary biology, oncology R&D or productivity, not generic “AI can discover molecules” stories.
Repeat acquirers are the best evidence that this is becoming strategic. RadNet, GE HealthCare, Innovaccer and IKS Health are stacking assets around category theses instead of buying random AI tools.
So, all things considered, healthcare AI M&A is not mainly about replacing doctors. The money is flowing first toward practical AI that collects revenue, reads images, reviews records, supports clinicians, activates patients and makes healthcare operations less broken.
This market map, featured in our healthcare AI market deck, highlights top companies and startups in the healthcare AI market
What are all the recent deals and acquisitions in the healthcare AI market?
When we look at all the M&A deals in the healthcare AI market over the last 24 months, the market is already deep enough to analyze like a real consolidation market.
We found 30 relevant healthcare AI M&A deals between 29 June 2024 and 29 June 2026, including 21 deals in the last 12 months.
| Date | Target | Acquirer | Value | Strategic rationale | Status and additional comment |
|---|---|---|---|---|---|
| Jun 2026 | Linkwell Health | DUOS | Undisclosed | Add AI-driven health-plan activation and member engagement | Acquired. Linkwell serves 20+ health plans and reaches roughly 1 in 5 U.S. adults |
| Jun 2026 | Loyal Health | Clarify Health | Undisclosed | Combine network intelligence with AI patient activation | Acquired. Useful because AI is moving into patient acquisition and engagement |
| May 2026 | CaduceusHealth | Innovaccer | Undisclosed | Build autonomous revenue cycle management for ambulatory providers | Asset acquisition. Caduceus manages around $5B in annual gross patient charges |
| May 2026 | Press Ganey Forsta | Qualtrics | $6.75B including debt | Combine healthcare experience data with AI experience-management tools | Closed. Largest disclosed healthcare AI-related deal in this 24-month window |
| May 2026 | ARAI Solutions | IKS Health | Undisclosed | Add agentic AI and biomedical knowledge graphs | Acquired. Shows IKS building more healthcare-specific AI capability internally |
| Apr 2026 | Alora Healthcare Systems | LivTech | Undisclosed | Build AI-powered home health and post-acute software | Acquired. Shows AI consolidation beyond hospitals, into home health |
| Mar 2026 | ThinkDTM | IKS Health | Undisclosed | Add AI-led product talent for patient access workflows | Acquihire. More about team and capability than standalone revenue scale |
| Mar 2026 | Gleamer | RadNet / DeepHealth | Up to €230M | Build the largest radiology clinical AI platform | Announced. Gleamer expected around $30M ARR in 2026, implying roughly 7.7x forward ARR |
| Jan 2026 | Kaia Health | Sword Health | $285M | Consolidate AI-first musculoskeletal digital care | Announced. Expands Sword’s footprint in the U.S. and Germany |
| Jan 2026 | Modella AI | AstraZeneca | Undisclosed | Add oncology foundation models and AI agents for R&D | Acquired. Shows pharma buying healthcare AI capability directly |
| Dec 2025 | Teyame.AI assets | Healthcare Triangle | Undisclosed | Add AI omnichannel customer engagement for healthcare and life sciences | Pending or not confirmed closed. Target was said to be on track for $34M FY2025 revenue |
| Nov 2025 | Intelerad | GE HealthCare | $2.3B | Expand cloud imaging software and AI-powered imaging workflows | Closed. One of the largest strategic imaging software deals |
| Nov 2025 | MedEvolve | Emergence | Undisclosed | Scale AI-powered revenue cycle management | Acquired. MedEvolve brings workflow data from millions of RCM actions |
| Nov 2025 | EyePACS | Optain Health | Undisclosed | Combine retinal imaging, AI screening and teleophthalmology | Acquired. EyePACS had identified 140,000+ patients with sight-threatening disease |
| Oct 2025 | Together by Renee | Cairns Health | Undisclosed | Add AI-powered chronic and senior-care app capability | Acquired. Smaller deal, but useful for AI care-navigation consolidation |
| Sep 2025 | HFMA MAP App | CareCloud | Undisclosed | Infuse AI into hospital RCM benchmarking | Acquired. No material 2025 financial impact communicated |
| Sep 2025 | DigitalOwl | Datavant | Undisclosed | Use AI to review medical records faster | Acquired. Relevant to insurance, legal and health-data workflows |
| Sep 2025 | Story Health | Innovaccer | Undisclosed | Add AI-enabled specialty care operations | Acquired. Strengthens Innovaccer’s clinical workflow layer |
| Sep 2025 | ZignaAI | Cohere Health | Undisclosed | Launch AI-powered payment integrity tools | Acquired. Adds NLP and machine learning for claims and payment workflows |
| Aug 2025 | Paige | Tempus AI | $81.25M | Add digital pathology AI and pathology-slide data | Acquired. Paige had nearly 7M digitized pathology slides |
| Jul 2025 | Iodine Software | Waystar | $1.25B | Add clinical intelligence to AI-enabled revenue cycle management | Closed Oct 2025. Waystar’s first acquisition since IPO |
| May 2025 | VirtuOx | Resmed | Undisclosed | Expand virtual diagnostics in sleep, respiratory and cardiac care | Acquired. Borderline AI, but relevant to digital diagnostics infrastructure |
| Apr 2025 | iCAD | RadNet / DeepHealth | About $103M | Add breast imaging AI to cancer-screening platform | Closed Jul 2025. iCAD adds AI breast-health tools across many provider sites |
| Mar 2025 | ModMed majority stake | Clearlake Capital | $5.3B valuation | Back AI-enabled specialty practice software | Majority investment. Large vertical healthcare software deal |
| Jan 2025 | Humbi AI | Innovaccer | Undisclosed | Add actuarial AI and payer-provider contracting tools | Acquired. Humbi data covers 200M+ lives |
| Jan 2025 | Machinify | New Mountain Capital | Undisclosed | Build AI-driven healthcare payment platform | Acquired. Combined into a roughly $5B medical-payments platform |
| Aug 2024 | care.ai | Stryker | Undisclosed | Add virtual care and ambient intelligence | Closed Sep 2024. Strategic fit with connected care and smart-room workflows |
| Aug 2024 | Exscientia | Recursion | $688M | Combine two AI drug discovery platforms | Closed Nov 2024. All-stock deal between two public AI drug discovery companies |
| Jul 2024 | Augmedix | Commure | $139M | Add ambient clinical documentation to healthcare AI platform | Closed Oct 2024. Implied around 2.5x to 2.7x guided 2024 revenue |
| Jul 2024 | Intelligent Ultrasound clinical AI business | GE HealthCare | About $51M | Add real-time ultrasound image-recognition AI | Closed Oct 2024. Direct clinical AI acquisition inside imaging |
Is healthcare AI M&A actually active now?
Yes, healthcare AI M&A is clearly active now. We found 30 relevant healthcare AI M&A deals in 24 months, which is too many to treat the market as a few random strategic experiments.
The better proof is the pace change. The previous 12 months had 9 deals, while the most recent 12 months had 21. That means the deal count increased by 12 deals, or about 133%, and the recent period was roughly 2.3x more active than the earlier one.
The first half of 2026 makes the acceleration harder to ignore. In only six months, we found 10 deals, including Qualtrics buying Press Ganey Forsta, RadNet buying Gleamer, Sword buying Kaia Health, AstraZeneca buying Modella AI, Innovaccer buying CaduceusHealth, and IKS Health buying ARAI Solutions. That six-month period alone represents one third of all the deals in the full 24-month window.
At the end of the day, healthcare AI M&A is already happening at platform-consolidation speed, especially in categories where AI is attached to revenue, imaging, care operations or proprietary healthcare data.
As this chart shows, and as featured in our healthcare AI market deck, search interest in healthcare AI has grown rapidly
Is healthcare AI M&A accelerating recently, or was it already hot before?
Healthcare AI M&A was already active before, but it has accelerated recently. The earlier period had meaningful deals, but the most recent 12 months changed the density and the variety of the market.
From 29 June 2024 to 28 June 2025, the big signals were concentrated in a few areas: Commure bought Augmedix for ambient documentation, Recursion bought Exscientia for AI drug discovery, Stryker bought care.ai for ambient intelligence, and RadNet started building its imaging AI position with iCAD. That was already a real market.
From 29 June 2025 to 29 June 2026, the activity widened. We see Waystar buying Iodine in AI revenue cycle management, Tempus buying Paige in digital pathology AI, GE HealthCare buying Intelerad in imaging software, Qualtrics buying Press Ganey Forsta in healthcare experience data, and multiple smaller AI deals around payment integrity, patient access, RCM, home health, specialty care and member activation.
The market has expanded from a few obvious AI categories into the operating layer of healthcare. So yes, it was already active, but the recent phase looks much more like infrastructure consolidation.
Are the biggest healthcare AI buyers buying models, or something else?
The biggest healthcare AI buyers are buying much more than models. They are buying workflow control, proprietary data, distribution, customer trust and healthcare-specific operating context.
Look at the large disclosed deals. Qualtrics paid $6.75B for Press Ganey Forsta because patient and employee experience data becomes more valuable when it feeds AI experience-management tools. GE HealthCare paid $2.3B for Intelerad because imaging AI is more useful when it sits inside cloud PACS, workflow orchestration and image-sharing infrastructure. Waystar paid $1.25B for Iodine because revenue cycle AI is stronger when it has clinical documentation intelligence before billing happens.
The smaller deals point in the same direction. Tempus bought Paige for digital pathology AI, but also for slide data and a technical team. Innovaccer bought CaduceusHealth to bring thousands of providers and billions of annual patient charges into its autonomous RCM workflow. IKS bought ARAI Solutions to own agentic AI and biomedical knowledge graph capabilities instead of depending only on external models.
The useful conclusion is simple: healthcare AI M&A is less about who has the prettiest model demo and more about who can put AI inside a real healthcare process where money, time or clinical work actually moves.
If you want more recent data on this point, please see our latest healthcare AI market report.
This chart, featured in our healthcare AI market deck, shows annual VC investment in healthcare AI startups
Is healthcare AI M&A still mostly about clinical AI?
No, healthcare AI M&A is not mostly about clinical AI these days. Clinical AI remains important, but administrative and financial AI are producing a huge share of the deal flow.
We classified roughly 9 to 10 deals as revenue cycle, payment, payer, claims, actuarial or healthcare finance related. That includes Waystar / Iodine, Innovaccer / CaduceusHealth, Innovaccer / Humbi AI, Cohere / ZignaAI, Emergence / MedEvolve, IKS / ARAI Solutions, IKS / ThinkDTM, CareCloud / MAP App and New Mountain / Machinify. That is one of the densest clusters in the dataset.
The reason is practical. Hospitals and clinics do not need to wait years to know whether RCM AI works. If AI reduces denials, speeds coding, improves documentation, supports payment integrity or fixes patient access, the buyer can link the tool to dollars. That makes the business case easier than many clinical AI categories, where adoption can be slower because regulation, physician trust and patient-risk questions are heavier.
So we can conclude that healthcare AI M&A is being pulled toward the back office first. That sounds less glamorous than diagnosis or drug discovery, but it is exactly where buyers can see the ROI fastest.
Is radiology AI consolidating again?
Yes, radiology AI is consolidating again, and it is the clearest clinical AI consolidation zone in healthcare right now. Imaging has digital data, high reading volume, visible labor pressure and established hospital budgets, which makes it a natural home for AI M&A.
RadNet / DeepHealth is the strongest example. It bought iCAD for breast imaging AI, then bought Gleamer for up to €230M. Gleamer expected around $30M ARR in 2026, so the transaction gives us a rare valuation datapoint of roughly 7.7x forward ARR if we use the full consideration. RadNet also said the combined DeepHealth platform could approach or exceed $140M ARR by the end of 2026, which makes this look like a real software platform rather than a single AI feature.
GE HealthCare is moving in the same direction from the medtech side. It bought Intelligent Ultrasound’s clinical AI business, then bought Intelerad for $2.3B to add cloud imaging software, workflow orchestration and AI-enabled enterprise imaging. Tempus buying Paige adds a third angle: pathology AI is moving closer to precision medicine, not staying isolated as a narrow image-reading tool.
All things considered, imaging AI is already past the “can this become a product?” stage. The current question is who controls the imaging workflow, the distribution and the datasets.
If you want more recent data on this point, please see our latest healthcare AI market report.
This chart, featured in our healthcare AI market deck, looks at Tempus AI’s strategy in healthcare AI
Are healthcare AI acquirers paying real money now?
Yes, healthcare AI acquirers are paying real money now, although most deal values are still not disclosed. We found 12 disclosed or semi-disclosed deals out of 30, so roughly 40% had visible valuation information and roughly 60% were undisclosed.
The disclosed value pool is large. Across the disclosed or semi-disclosed transactions, we get more than $17B in announced or indicated value. The largest deals are Qualtrics / Press Ganey Forsta at $6.75B, Clearlake / ModMed at a $5.3B valuation, GE HealthCare / Intelerad at $2.3B, Waystar / Iodine at $1.25B, Recursion / Exscientia at $688M, Sword / Kaia Health at $285M, RadNet / Gleamer at up to €230M, Commure / Augmedix at $139M, RadNet / iCAD at about $103M, and Tempus / Paige at $81.25M.
The distribution matters more than the total number. This is not one mega-deal hiding a dead market. We have several large deals above $1B, mid-sized transactions in the $80M to $300M range, and many undisclosed capability deals below the radar. That mix usually appears when a market has both strategic urgency and many product gaps left to fill.
So yes, buyers are paying. But they are paying the most when the target brings a defensible workflow, a large dataset, recurring software revenue or direct access to healthcare customers.
Is healthcare AI M&A being driven by strategic buyers or financial sponsors?
Healthcare AI M&A is mostly driven by strategic buyers in deal count, while financial sponsors are important for the biggest platform-building moves.
Most visible acquirers are operating companies. GE HealthCare, RadNet / DeepHealth, Waystar, Tempus, Innovaccer, IKS Health, Stryker, AstraZeneca, Sword Health, Datavant, Cohere Health, Clarify Health, DUOS and Resmed are buying products, data, teams or workflows they can plug into their existing business. These deals look operational rather than purely financial.
Financial sponsors still matter because they help create larger healthcare software platforms. Clearlake’s ModMed investment at a $5.3B valuation and New Mountain’s Machinify-led payment platform show that private equity sees AI as a way to upgrade healthcare vertical software and payment infrastructure. Qualtrics / Press Ganey Forsta also has a financial-sponsor context because Qualtrics is backed by Silver Lake and CPP Investments.
The cleaner way to say it is this: strategics are buying the pieces, while sponsors are backing the platforms. Both are active, but they are not playing the same role.
If you want more recent data on this point, please see our latest healthcare AI market report.
This chart, featured in our healthcare AI market deck, shows annual funding in healthcare AI startups
Are healthcare AI deals happening only in the U.S.?
No, healthcare AI M&A is not only U.S.-based, but the commercial center of gravity is clearly the United States. The reason is not that all the best AI healthcare companies are American. It is that U.S. healthcare has massive administrative cost, payer complexity, private reimbursement workflows and software budgets that make AI monetization easier to justify.
Most of the biggest workflow deals are U.S.-anchored. Waystar / Iodine is about U.S. revenue cycle management. Innovaccer / CaduceusHealth is about U.S. ambulatory billing. Qualtrics / Press Ganey Forsta is tied to a massive healthcare experience footprint. DUOS / Linkwell Health is about health-plan activation. Cohere / ZignaAI sits in payment integrity. These are all areas where U.S. healthcare complexity creates an automation budget.
But the technology supply is international. Recursion bought U.K.-origin Exscientia. RadNet bought France-based Gleamer. Sword bought Kaia Health, which expands the footprint in the U.S. and Germany. GE HealthCare bought Intelligent Ultrasound’s clinical AI business, also U.K.-linked. Healthcare Triangle moved toward Spain-based Teyame.AI assets.
So it looks like healthcare AI M&A is global in talent and technology, but U.S.-anchored in monetization. That is an important distinction because it explains why many non-U.S. AI assets can still end up inside U.S.-heavy commercial platforms.
Is AI drug discovery still a strong M&A theme now?
AI drug discovery is still a real M&A theme, but it is not the highest-volume M&A category in healthcare AI right now. It has produced important consolidation signals, just not as many transactions as RCM, imaging or care operations.
The Recursion / Exscientia deal is the cleanest signal. It combined two public AI drug discovery companies in a $688M all-stock transaction, creating a vertically integrated AI-enabled drug discovery platform. That deal was not a small tuck-in but more like a reset of the standalone AI biotech category, where scale, cash runway, pipeline depth and data infrastructure matter.
AstraZeneca buying Modella AI gives a second, different signal. Instead of one AI discovery company merging with another, a large pharma buyer acquired AI capability directly for oncology R&D, including foundation models and AI agents. That suggests pharma still wants AI, but the preferred model may be targeted capability acquisition rather than buying broad standalone platforms at any price.
In the end, AI drug discovery M&A is selective, not dead. The market has become more demanding: buyers want AI tied to pipelines, proprietary biology, oncology workflows or R&D productivity, not just a generic claim that machine learning can find better molecules.
If you want more recent data on this point, please see our latest healthcare AI market report.
This chart, featured in our healthcare AI market deck, compares the main business model options for ambient AI companies
Are small healthcare AI startups being bought for revenue or for capability?
Many smaller healthcare AI startups are being bought for capability, team, data or product gaps, not only for current revenue. That matters because undisclosed deal values can make the market look quieter than it actually is.
Several transactions look capability-led. IKS Health acquihired ThinkDTM for AI-led digital product talent, then bought ARAI Solutions for agentic AI, biomedical knowledge graphs and explainable AI. Cohere Health bought ZignaAI to launch payment integrity tools. Datavant bought DigitalOwl to speed up medical-record review with AI. Cairns Health bought Together by Renee to add AI-powered senior and chronic-care support. Clarify Health bought Loyal Health to connect network intelligence with patient activation.
The pattern is useful because it shows two layers of consolidation. The top layer is headline M&A, with billion-dollar deals and disclosed values. The lower layer is capability M&A, where platforms buy missing modules before competitors can build them.
When we look only at disclosed values, we miss a large part of what is happening. A lot of healthcare AI M&A is about filling holes in the platform before the market standard gets locked in.
Are healthcare AI buyers coming back for multiple acquisitions again?
Yes, repeat buyers are one of the strongest signs that healthcare AI M&A is becoming more strategic. A buyer that acquires once may be experimenting. A buyer that acquires two or three times is usually building a position.
RadNet / DeepHealth bought iCAD and then Gleamer, which shows a clear push to build a radiology clinical AI platform. GE HealthCare bought Intelligent Ultrasound’s clinical AI business and then Intelerad, moving from AI functionality into broader cloud imaging infrastructure. Innovaccer bought Humbi AI, Story Health and CaduceusHealth, which points toward a wider healthcare intelligence and autonomous workflow platform. IKS Health did ThinkDTM and ARAI Solutions, both linked to AI capability and healthcare operations.
As we saw above, these repeat buyers are not buying random companies across unrelated categories. They are stacking assets around a thesis: radiology AI, imaging infrastructure, autonomous RCM, payer-provider intelligence, patient access or healthcare-specific agentic AI.
That is why repeat acquirers matter so much here. They show that healthcare AI M&A is becoming a build-or-buy race around category ownership.
This chart, featured in our healthcare AI market deck, illustrates how revenue is distributed across customer segments in the healthcare AI market
Is healthcare AI M&A more about replacing doctors or fixing healthcare operations?
Right now, healthcare AI M&A is more about fixing healthcare operations than replacing doctors. The deal list is much more concentrated around workflow, billing, documentation, imaging productivity, patient access, engagement and data review than around autonomous clinical decision-making.
The evidence is very direct. Waystar / Iodine, Innovaccer / CaduceusHealth, Cohere / ZignaAI, MedEvolve / Emergence, CareCloud / MAP App and Machinify are all about money flow, coding, payment, claims or finance. Commure / Augmedix and Stryker / care.ai are about documentation, ambient intelligence and clinical workflow support. Clarify / Loyal, DUOS / Linkwell and Cairns / Together by Renee are about engagement, navigation and activation.
Even in clinical categories, the theme is usually augmentation. Radiology AI helps with detection, triage, workflow and productivity. Pathology AI supports precision medicine and data interpretation. Oncology R&D AI supports research productivity. These are not deals built around a simple “AI replaces clinician” story.
The more accurate conclusion is that healthcare AI M&A is monetizing around the boring bottlenecks first. The strongest acquisition demand is where AI saves time, reduces leakage, organizes data or increases throughput.
If you want more recent data on this point, please see our latest healthcare AI market report.
So, what is the latest update on M&A in the healthcare AI market?
The latest update is that healthcare AI M&A has moved from scattered experimentation to active platform consolidation.
The market is currently strongest where AI is attached to measurable workflows: revenue cycle management, payment integrity, imaging, clinical documentation, patient engagement, specialty care and healthcare data infrastructure.
| Check | Current status |
|---|---|
| Recent deal volume | Healthcare AI M&A is clearly active now. We found 30 deals in 24 months, including 21 in the most recent 12 months. |
| Acceleration | The market accelerated sharply. The last 12 months had about 2.3x more deals than the previous 12 months. |
| Six-month momentum | The first half of 2026 alone had 10 deals. That means momentum is still current, not just a 2025 story. |
| Disclosed value | Disclosed and semi-disclosed value reached more than $17B across 12 deals. The market has several large outcomes, not just one isolated mega-deal. |
| Value opacity | Roughly 60% of deal values were undisclosed. That means public deal value understates the amount of strategic activity. |
| Biggest buyer motive | Buyers are mainly acquiring workflow, data, distribution and healthcare-specific context. The model alone is rarely the whole asset. |
| Busiest category | Administrative AI is the busiest area. RCM, claims, payment integrity, actuarial tools, billing and patient access show repeated M&A signals. |
| Clinical AI hotspot | Imaging AI is the strongest clinical consolidation area. RadNet / DeepHealth and GE HealthCare are the clearest repeat buyers. |
| Life sciences AI | AI drug discovery and oncology R&D are still active, but more selective. Recursion / Exscientia and AstraZeneca / Modella AI are the key signals. |
| Buyer type | Strategic buyers dominate deal count, while financial sponsors help create larger healthcare software platforms. |
| Geography | The market is global in technology supply but U.S.-anchored in monetization. U.S. healthcare complexity creates many of the strongest AI automation budgets. |
| Repeat acquirers | Repeat buyers are now visible. RadNet, GE HealthCare, Innovaccer and IKS Health are buying multiple assets around specific platform theses. |
| Bottom line | Healthcare AI M&A is accelerating now, but the money is flowing toward practical AI. Buyers want AI that collects revenue, reads images, reviews records, supports clinicians, activates patients or makes healthcare operations less broken. |
This chart, featured in our healthcare AI market deck, shows how symptom checker app technology has evolved over time
OUR METHODOLOGY
This analysis tests what is happening now in healthcare AI M&A based on recent transaction evidence. We compare deal pace, category concentration, buyer type, disclosed value, repeat acquirers, geography and strategic rationale to understand whether the market is still experimental or already consolidating.
We treated healthcare AI M&A as a question that cannot be answered cleanly from intuition alone. So we broke the question into the signals that best reveal actual market behavior: who is buying, what they are buying, how often they are buying, where disclosed money is appearing, and which categories keep repeating.
We focused on recent transactions because M&A shows where buyers are actually committing capital, not just where the market narrative is loud. The core window covers deals identified between 29 June 2024 and 29 June 2026.
We counted relevant healthcare AI transactions when AI was central to the target, the rationale, the product layer, the operating workflow, the healthcare data asset, or the buyer’s stated strategic direction. We included both pure AI companies and healthcare software or infrastructure assets where AI was a major part of the acquisition logic.
We separated disclosed, semi-disclosed and undisclosed deals because headline value alone gives a distorted view of the market. Many of the most important capability acquisitions have undisclosed values, but they still show where platforms are filling product, data and workflow gaps.
We paid special attention to repeat acquirers because they reveal strategic intent better than one-off transactions. RadNet / DeepHealth, GE HealthCare, Innovaccer and IKS Health were especially useful because they show buyers stacking assets around clearer platform theses.
We also separated clinical AI from administrative and operational AI. That distinction matters because imaging, pathology and drug discovery follow a different adoption logic from RCM, payment integrity, claims review, patient access, documentation and member engagement.
For geography, we looked at both the origin of the target and the likely commercial monetization layer. That is why the analysis distinguishes between global technology supply and the U.S.-anchored revenue opportunity created by reimbursement complexity, payer workflows and healthcare software budgets.
We prioritized sources that added specific, checkable information: deal value, target and acquirer names, transaction status, strategic rationale, revenue or ARR references, data-scale references, platform context and buyer commentary. We excluded recycled aggregation pages and commentary that repeated deal announcements without adding useful evidence.
Key sources used for this analysis include: Financial Times on Qualtrics / Press Ganey Forsta, Barron’s on GE HealthCare / Intelerad, The Wall Street Journal on Waystar / Iodine Software, The Times on Recursion / Exscientia, The Economic Times on Innovaccer / CaduceusHealth, Business Insider on healthcare startup acquisition appetite, Business Insider on Commure context, Investopedia on GE HealthCare and Intelligent Ultrasound context, Cinco Días on Qualtrics / Press Ganey, Reuters on Recursion / Exscientia, Reuters on AstraZeneca / Modella AI, GE HealthCare’s Intelligent Ultrasound announcement, GE HealthCare’s Intelerad announcement, Datavant’s DigitalOwl announcement, Datavant’s Ontellus announcement, RadNet / DeepHealth’s iCAD announcement, Commure’s Augmedix announcement, Stryker’s care.ai announcement, Clearlake / ModMed announcement, Innovaccer / Humbi AI announcement, Cohere Health / ZignaAI announcement, and Clarify Health / Loyal announcement.
In our healthcare AI market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- How strong is fundraising in the healthcare AI market right now?
- Which startups have raised the most funding in the healthcare AI market?
- Which startups are the most valued in the healthcare AI market?
